focus -WSS

focus

author：hotspot 2025-09-28 13:22:35 Page View：9

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Death toll from an explosion and collapse of a Paris building in June climbs to 3
Next article： Virginia high school admissions case could be legal follow

knowledge

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

What to know about Saharan dust affecting the US and how it can affect health

1:03InthisJuly13,2023filephotopeopleenjoythesunrisingovertheAtlanticOceanonJuly13,2023inMiamiBeach,F

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Our daughter's deadly disease: trisomy 18. We wanted to protect her

MariaFabrizioforSTAT“Issheinpain?”Iaskedquietlyasthepearlescentbaby-shapedimageonthescreenfoldeditsl

focus

explore

knowledge

Our daughter's deadly disease: trisomy 18. We wanted to protect her